You are here

Share:

Search Technologies

Showing 1-20 of 93 results found

Use of Replicators in Gene Therapy

This technology is a method of inhibiting or delaying gene silencing through specific transgene constructs that would be used for generating gene therapy vectors.

Nitric Oxide-Releasing Polysaccharide Materials

Researchers at the National Cancer Institute have developed materials derived from polysaccharides that are capable of releasing nitric oxide into the surrounding environment. These materials could be incorporated into surgical dressings, cotton bandages, cellulose filters and dialysis membranes, or other medical devices

Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles

Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.

Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents

Researchers at the National Cancer Institute (NCI) have developed several novel small-molecule inhibitors directed against HPPK, a bacterial protein, as potential antimicrobial agents. The NCI seeks co-development partners or licensees to further develop these novel small-molecule HPPK inhibitors as broad-spectrum bactericidal agents.

Increased Therapeutic Effectiveness of PE-Based Immunotoxins

To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human B cell epitopes within PE. Previous work demonstrated that the removal of the murine B cell and T cell epitopes from PE reduced the immunogenicity of PE and resulted in immunotoxins with improved therapeutic activity. The National Cancer Institute's Laboratory of Molecular Biology seeks interested parties to co-develop and commercialize immunotoxins using toxin domains lacking human B cell epitopes.

Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors

Scientists at National Cancer Institute (NCI) Center for Cancer Research (CCR) identified selective tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors that may be used in combination with topoisomerase 1 (TOP1) inhibitors for synergistic treatment of solid tumors. NCI seeks research co-development partners and/or licensees for commercializing the TDP1 inhibitors as part of an anti-cancer therapy.

Novel Fusion Proteins for HIV Vaccine

The National Cancer Institute’s Cancer and Inflammation Program seeks parties to license gp120 and CD4-induced antibody fusion proteins for use in an HIV vaccine.

Chimeric Antigen Receptors to CD276 for Treating Cancer

This licensing opportunity from the National Cancer Institute concerns the development of CARs comprising an antigen-binding fragment derived from the MGA271 antibody. The resulting CARs can be used in adoptive cell therapy treatment for neuroblastoma and other tumors that express CD276.

Molecular Nanotags for Detection of Single Molecules

Researchers at the National Cancer Institute (NCI) developed novel molecular nanotags for single biological nanoparticle detection, resolution, and sorting, by flow cytometry. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations to further advance this technology with extremely broad biomedical, biodefense, industrial, environmental, and other applications.

Metformin for the Treatment of Age-related Retinal Degeneration

Researchers at the National Eye Institute (NEI) have generated Induced Pluripotent Stem Cells (iPS) from two Late-Onset Reginal (L-ORD) patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. All iPS cells were differentiated into authenticated Retinal Pigment Epithelium (RPE) cells. The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration.

Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants

Researchers at the National Cancer Institute (NCI) developed a novel biophysical technique to purify extracellular vesicles (EVs) from contaminants such as proteins and unbound labels. The NCI seeks licensees and/or co-development research collaborations to further advance this technology for EV-based biomarkers and therapeutics to treat a wide range of diseases.

New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer

Researchers at the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have developed novel heterocyclic scaffold-based inhibitors of the polo-box domain (PBD) of Polo-like kinase 1 (Plk1). These compounds effectively arrest mitotic progression and cell proliferation in cell-based assays. The National Institutes of Health (NIH) seeks licensing and/or co-development research collaborations to further develop these inhibitors for the treatment of cancer.

Pages